Table 4.
BAL cytological pattern, lung function tests parameters, laboratory results, % of patients on treatment and time from first symptoms to visit 1 in sarcoidosis patients divided according to radiological stage.
| Stage I | Stage II | Stage III | Difference | |
|---|---|---|---|---|
| BAL lymphocytes (%) | 29.6 ± 3.5 | 34.9 ± 7.3 | 32.8 ± 7.0 | NS |
| BAL lymphocytes (× 104/mL) | 5.03 ± 1.08 | 8.5 ± 2.7 | 10.98 ± 4.15 | NS |
| BAL neutrophils (%) | 1 ± 0.33 (1) [0-1] |
1.13 ± 0.4 (1) [0-2] |
0.33 ± 0.21 (0) [0-5] |
NS |
| BAL neutrophils (× 104/mL) |
0.15 ± 0.06 | 0.22 ± 0.08 | 0.23 ± 0.22 | NS |
| BAL eosinophils (%) | 1.17 ± 0.25 (1) [0.5-1.5] |
0.75 ± 0.25 (1) [0-1] |
0.72 ± 0.32 (1) [0-5] |
NS |
| BAL eosinophils (× 104/mL) |
0.14 ± 0.03 | 0.16 ± 0.25 | 0.72 ± 0.32 | p ≤ 0.01: I vs III p ≤ 0.05: II vs III |
| FEV1 (% predicted) | 99.4 ± 3.5 | 81.1 ± 7.5 | 87.8 ± 7.0 | p ≤ 0.05: I vs II |
| FVC (% predicted) | 104.7 ± 3.5 | 84.8 ± 7.0 | 94.9 ± 4.0 | p ≤ 0.05: I vs II |
| FEV1/FVC (%) | 0.83 ± 0.02 | 0.78 ± 0.04 | 0.77 ± 0.04 | NS |
| DLCOc (% predicted) | 96.8 ± 4.4 | 77.4 ± 6.0 | 77.1 ± 6.3 | p ≤ 0.05: I vs II&III |
| SACE (IU/L) | 65.8 ± 8.6 | 98.8 ± 30.3 | 45.8 ± 12.8 | NS |
| S-Ca2+(mmol/L) | 2.46 ± 0.02 | 2.44 ± 0.08 | 2.50 ± 0.02 | NS |
| U-Ca2+(mmol/24 h) | 5.25 ± 0.48 | 5.15 ± 0.94 | 4.52 ± 0.83 | NS |
| CRP (mg/L) | 7.30 ± 2.27 (5.0) [1.5-7.1] |
19.85 ± 8.77 (9.4) [4.6-25.3] |
4.40 ± 1.71 (2.5) [0.7-6.7] |
NS |
| T from onset to V1 (weeks) |
38 ± 25 (8) [4-24] |
107 ± 50 (8) [4-238] |
149 ± 55 (88) [18-289] |
p ≤ 0.05: I vs III |
| LS | 15/23 | 5/9 | 0/8 | - |
DLCOc -- diffusion capacity for CO corrected for hemoglobin, FEV1 -- forced expiratory volume in 1st second of expiration, FVC -- forced vital capacity,
LS -- Löfgren syndrome, S -- serum, SACE -- serum angiotensin converting enzyme, T -- time, U -- urine, V1 -- visit 1.